These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
584 related articles for article (PubMed ID: 32459948)
21. Case report study of the first five COVID-19 patients treated with remdesivir in France. Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764 [TBL] [Abstract][Full Text] [Related]
23. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. Montastruc F; Thuriot S; Durrieu G Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2835-2836. PubMed ID: 32721580 [TBL] [Abstract][Full Text] [Related]
24. [From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic]. Estella Á; Garnacho-Montero J Med Intensiva (Engl Ed); 2020 Nov; 44(8):509-512. PubMed ID: 32423569 [No Abstract] [Full Text] [Related]
25. [Not Available]. Fumeaux T Rev Med Suisse; 2020 Jun; 16(697):1220. PubMed ID: 32520466 [No Abstract] [Full Text] [Related]
26. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient. Hillaker E; Belfer JJ; Bondici A; Murad H; Dumkow LE Pharmacotherapy; 2020 Jun; 40(6):592-598. PubMed ID: 32281114 [TBL] [Abstract][Full Text] [Related]
27. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. Goldman JD; Lye DCB; Hui DS; Marks KM; Bruno R; Montejano R; Spinner CD; Galli M; Ahn MY; Nahass RG; Chen YS; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wei X; Gaggar A; Brainard DM; Towner WJ; Muñoz J; Mullane KM; Marty FM; Tashima KT; Diaz G; Subramanian A; N Engl J Med; 2020 Nov; 383(19):1827-1837. PubMed ID: 32459919 [TBL] [Abstract][Full Text] [Related]
28. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. Adamsick ML; Gandhi RG; Bidell MR; Elshaboury RH; Bhattacharyya RP; Kim AY; Nigwekar S; Rhee EP; Sise ME J Am Soc Nephrol; 2020 Jul; 31(7):1384-1386. PubMed ID: 32513665 [No Abstract] [Full Text] [Related]
29. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516 [No Abstract] [Full Text] [Related]
30. Compassionate Use of Remdesivir for Patients with Severe Covid-19. Grein J; Ohmagari N; Shin D; Diaz G; Asperges E; Castagna A; Feldt T; Green G; Green ML; Lescure FX; Nicastri E; Oda R; Yo K; Quiros-Roldan E; Studemeister A; Redinski J; Ahmed S; Bernett J; Chelliah D; Chen D; Chihara S; Cohen SH; Cunningham J; D'Arminio Monforte A; Ismail S; Kato H; Lapadula G; L'Her E; Maeno T; Majumder S; Massari M; Mora-Rillo M; Mutoh Y; Nguyen D; Verweij E; Zoufaly A; Osinusi AO; DeZure A; Zhao Y; Zhong L; Chokkalingam A; Elboudwarej E; Telep L; Timbs L; Henne I; Sellers S; Cao H; Tan SK; Winterbourne L; Desai P; Mera R; Gaggar A; Myers RP; Brainard DM; Childs R; Flanigan T N Engl J Med; 2020 Jun; 382(24):2327-2336. PubMed ID: 32275812 [TBL] [Abstract][Full Text] [Related]
31. Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic. Kouzy R; Abi Jaoude J; Garcia Garcia CJ; El Alam MB; Taniguchi CM; Ludmir EB JAMA Netw Open; 2020 Jul; 3(7):e2015100. PubMed ID: 32658285 [TBL] [Abstract][Full Text] [Related]
32. Uncertainty about the Efficacy of Remdesivir on COVID-19. Yoo JH J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956 [No Abstract] [Full Text] [Related]
33. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584 [TBL] [Abstract][Full Text] [Related]
34. [COVID-19: a cardiological point-of-view]. Weckbach LT; Kellnar A; Stremmel C; Stark K; Kääb S Dtsch Med Wochenschr; 2020 Jul; 145(15):1063-1067. PubMed ID: 32731280 [TBL] [Abstract][Full Text] [Related]
35. Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis. Shih WJ; Yao C; Xie T Ther Innov Regul Sci; 2020 Sep; 54(5):1236-1255. PubMed ID: 32865809 [TBL] [Abstract][Full Text] [Related]
36. [Chloroquine as a possible treatment for COVID-19]. Coumou J; de Vries PJ Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391999 [TBL] [Abstract][Full Text] [Related]
37. Repurposing antimalarials and other drugs for COVID-19. Schlagenhauf P; Grobusch MP; Maier JD; Gautret P Travel Med Infect Dis; 2020; 34():101658. PubMed ID: 32247925 [No Abstract] [Full Text] [Related]
38. Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials. Yokoyama Y; Briasoulis A; Takagi H; Kuno T Virus Res; 2020 Oct; 288():198137. PubMed ID: 32827627 [TBL] [Abstract][Full Text] [Related]
39. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities. Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973 [No Abstract] [Full Text] [Related]
40. Dozens of coronavirus drugs are in development - what happens next? Ledford H Nature; 2020 May; 581(7808):247-248. PubMed ID: 32409766 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]